Literature DB >> 2680168

Insulin and glucagon degradation in liver are not affected by hepatic cirrhosis.

S Antoniello1, S La Rocca, E Cavalcanti, M Auletta, F Salvatore, L Cacciatore.   

Abstract

Hyperinsulinemia and impaired glucose tolerance are associated with liver cirrhosis. To investigate whether insulin-degrading activity in liver tissue plays a role in hyperinsulinemia, we assayed this activity in biopsy tissue from healthy and cirrhotic subjects. There was no difference in insulin degradation between these two groups. Also glucagon-degrading activity in liver tissue, which is catalyzed by the same enzyme as insulin-degrading activity, did not differ between the two groups studied. Therefore, insulin-degrading activity does not appear to be involved in the hyperinsulinemia that occurs in liver cirrhosis. The study provides indirect evidence that hyperinsulinemia and impaired glucose metabolism in liver cirrhosis are due to different mechanisms (receptorial and post-receptorial defects, and altered feedback inhibition of insulin secretion).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2680168     DOI: 10.1016/0009-8981(89)90369-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Decreased expression of insulin and increased expression of pancreatic transcription factor PDX-1 in islets in patients with liver cirrhosis: a comparative investigation using human autopsy specimens.

Authors:  Masahiro Sakata; Akihiko Kawahara; Takumi Kawaguchi; Jun Akiba; Tomoki Taira; Eitaro Taniguchi; Mitsuhiko Abe; Hironori Koga; Masayoshi Kage; Michio Sata
Journal:  J Gastroenterol       Date:  2012-07-12       Impact factor: 7.527

2.  Insulin Clearance Is Associated with Hepatic Lipase Activity and Lipid and Adiposity Traits in Mexican Americans.

Authors:  Artak Labadzhyan; Jinrui Cui; Miklós Péterfy; Xiuqing Guo; Yii-Der I Chen; Willa A Hsueh; Jerome I Rotter; Mark O Goodarzi
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.